Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient
- PMID: 21764887
- DOI: 10.1158/1078-0432.CCR-10-2051
Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient
Abstract
The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others.
©2011 AACR.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
